Form 4: Entrada Therapeutics CEO Sells Shares for Tax Obligations
Insider Transaction Report
Entrada Therapeutics CEO Dipal Doshi sold 8,723 shares to cover tax withholding obligations from RSU vesting.
Summary
- Dipal Doshi, CEO and Director of Entrada Therapeutics, Inc. (TRDA), disposed of 8,723 shares of common stock.
- The transaction occurred on September 2, 2025, at a weighted average price of $5.4302 per share.
- The shares were sold in multiple transactions with prices ranging from $5.36 to $5.58.
- The sale was made to cover tax withholding obligations related to the vesting of previously granted Restricted Stock Units (RSUs).
- Following this transaction, Dipal Doshi beneficially owns 415,664 shares of Entrada Therapeutics common stock.
- The transaction was made pursuant to a Rule 10b5-1(c) pre-arranged plan.
Sentiment
Score: 5
Explanation: The transaction is a routine, pre-planned sale to cover tax obligations from RSU vesting, which is a neutral event and does not indicate any significant positive or negative sentiment about the company's prospects.
Negatives
- A reduction in the direct beneficial ownership of common stock by the CEO, although for a routine tax purpose.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
This routine insider transaction, a sale to cover tax obligations from RSU vesting, is a common occurrence across all industries for executives receiving equity compensation. It does not reflect on broader industry trends or competitive positioning.
Stakeholder Impact
- Shareholders: The transaction represents a minor reduction in direct insider ownership, but for a routine tax purpose, it is unlikely to have a material impact on shareholder confidence or the company's valuation.
Key Dates
| Date | Description |
|---|---|
| 09/02/2025 | Date of transaction where shares were disposed of to cover tax withholding obligations. |
| 09/04/2025 | Date the Form 4 statement was signed and filed. |
Keywords
Entrada Therapeutics, TRDA, Dipal Doshi, CEO, Director, Form 4, Insider Trading, Stock Sale, RSU Vesting, Tax Withholding, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.